These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22488038)

  • 1. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer.
    Innominato PF; Giacchetti S; Bjarnason GA; Focan C; Garufi C; Coudert B; Iacobelli S; Tampellini M; Durando X; Mormont MC; Waterhouse J; Lévi FA
    Int J Cancer; 2012 Dec; 131(11):2684-92. PubMed ID: 22488038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
    Ortiz-Tudela E; Iurisci I; Beau J; Karaboue A; Moreau T; Rol MA; Madrid JA; Lévi F; Innominato PF
    Int J Cancer; 2014 Jun; 134(11):2717-25. PubMed ID: 24510611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.
    Innominato PF; Giacchetti S; Moreau T; Bjarnason GA; Smaaland R; Focan C; Garufi C; Iacobelli S; Tampellini M; Tumolo S; Carvalho C; Karaboué A; Poncet A; Spiegel D; Lévi F;
    Cancer; 2013 Jul; 119(14):2564-73. PubMed ID: 23633399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status.
    Mormont MC; Waterhouse J; Bleuzen P; Giacchetti S; Jami A; Bogdan A; Lellouch J; Misset JL; Touitou Y; Lévi F
    Clin Cancer Res; 2000 Aug; 6(8):3038-45. PubMed ID: 10955782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).
    Innominato PF; Giacchetti S; Moreau T; Smaaland R; Focan C; Bjarnason GA; Garufi C; Iacobelli S; Tampellini M; Tumolo S; Carvalho C; Karaboué A; Lévi F;
    Chronobiol Int; 2011 Aug; 28(7):586-600. PubMed ID: 21859417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
    Giacchetti S; Bjarnason G; Garufi C; Genet D; Iacobelli S; Tampellini M; Smaaland R; Focan C; Coudert B; Humblet Y; Canon JL; Adenis A; Lo Re G; Carvalho C; Schueller J; Anciaux N; Lentz MA; Baron B; Gorlia T; Lévi F;
    J Clin Oncol; 2006 Aug; 24(22):3562-9. PubMed ID: 16877722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
    Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
    Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
    J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer.
    Innominato PF; Focan C; Gorlia T; Moreau T; Garufi C; Waterhouse J; Giacchetti S; Coudert B; Iacobelli S; Genet D; Tampellini M; Chollet P; Lentz MA; Mormont MC; Lévi F; Bjarnason GA;
    Cancer Res; 2009 Jun; 69(11):4700-7. PubMed ID: 19470769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
    Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
    J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
    Yamazaki K; Kuwano H; Ojima H; Otsuji T; Kato T; Shimada K; Hyodo I; Nishina T; Shirao K; Esaki T; Ohishi T; Denda T; Takeuchi M; Boku N
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):569-77. PubMed ID: 25575764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival.
    Lévi F; Dugué PA; Innominato P; Karaboué A; Dispersyn G; Parganiha A; Giacchetti S; Moreau T; Focan C; Waterhouse J; Spiegel D;
    Chronobiol Int; 2014 Oct; 31(8):891-900. PubMed ID: 24927369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Home-Based e-Health Platform for Multidimensional Telemonitoring of Symptoms, Body Weight, Sleep, and Circadian Activity: Relevance for Chronomodulated Administration of Irinotecan, Fluorouracil-Leucovorin, and Oxaliplatin at Home-Results From a Pilot Study.
    Innominato P; Komarzynski S; Karaboué A; Ulusakarya A; Bouchahda M; Haydar M; Bossevot-Desmaris R; Mocquery M; Plessis V; Lévi F
    JCO Clin Cancer Inform; 2018 Dec; 2():1-15. PubMed ID: 30652550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy.
    Tampellini M; Polverari RS; Ottone A; Alabiso I; Baratelli C; Bitossi R; Brizzi MP; Leone F; Forti L; Bertona E; Racca P; Mecca C; Alabiso O; Aglietta M; Berruti A; Scagliotti GV
    Chronobiol Int; 2015; 32(10):1359-66. PubMed ID: 26540634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
    Cassinello J; Escudero P; Salud A; Marcos F; Pujol E; Pérez-Carrión R; Colmenarejo A; González del Val R; Valero J; Oruezábal MJ; Guillem V; García I; Arcediano A; Marfà X
    Clin Colorectal Cancer; 2003 Aug; 3(2):108-12. PubMed ID: 12952567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
    Lévi F; Focan C; Karaboué A; de la Valette V; Focan-Henrard D; Baron B; Kreutz F; Giacchetti S
    Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1015-35. PubMed ID: 17692427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.